Dose of nafamostat mesylate during continuous kidney replacement therapy in critically ill patients: a two-centre observational study.

Background: Nafamostat mesylate is an anticoagulant used for critically ill patients during continuous kidney replacement therapy (CKRT), characterised by its short half-life. However, its optimal dosage remains unclear. This study aimed to explore the optimal dosage of nafamostat mesylate during CKRT.

Catalytic selective ethane dehydrogenation at low-temperature with low coke formation.

Catalytic ethane dehydrogenation (EDH) was investigated to improve the efficient production of ethylene, an extremely important chemical feedstock. The perovskite oxide YCrO was found to be more suitable than earlier reported catalysts because it exhibits greater activity and CH selectivity (94.3%) in the presence of steam at 973 K.